Lead Product(s) : NMD670
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NMD Pharma Receives FDA IND Clearance for NMD670 in Myasthenia Gravis Phase 2b Trial
Details : NMD670 is a muscle-targeted small molecule inhibitor of the ClC-1 chloride ion channel. It is under evaluation for treating generalized myasthenia gravis in AChR or MuSK antibody-positive patients.
Product Name : NMD670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ALK Completes First Part of Phase 1 Trial with Peanut SLIT-tablet
Details : ALK Abello AS is developing sublingual immunotherapy (‘SLIT’) tablets and it is under phase 1 clinical development for the treatment of Peanut Allergy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alk Begins Clinical Trial of Its SLIT-tablet for the Treatment of Peanut Allergy
Details : ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 27, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable